02179 瑞科生物－Ｂ
按盤價 
4.080 0.000 (0.000%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 資產回報率 (%) | -32.976% | -27.257% | -25.444% | -34.180% | -44.336% |
| 股東資金回報率 (%) | -98.836% | -70.265% | -41.851% | -43.338% | -197.906% |
| 資本運用回報率 (%) | -49.885% | -51.089% | -32.833% | -36.489% | -36.943% |
邊際利潤分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 88.276% | N/A | N/A | N/A | N/A |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | -3628.556% | N/A | N/A | N/A | N/A |
| 稅前邊際利潤率 (%) | -4779.428% | N/A | N/A | N/A | N/A |
| 純利率 (%) | -4796.401% | N/A | N/A | N/A | N/A |
變現能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流動比率 (X) | 1.000 X | 0.780 X | 2.542 X | 4.316 X | 9.294 X |
| 速動比率 (X) | 0.924 X | 0.706 X | 2.331 X | 4.145 X | 9.125 X |
財務槓桿分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 總負債 / 總資產比率 (%) | 59.937% | 72.719% | 51.015% | 28.426% | 12.814% |
| 總債項 / 總資產比率 (%) | 36.239% | 45.824% | 29.767% | 12.237% | 3.997% |
| 淨債項 / 總資產比率 (%) | 16.269% | 29.381% | -8.425% | -45.139% | -57.619% |
| 總債項 / 股東資金比率 (%) | 90.456% | 167.968% | 60.740% | 17.007% | 4.585% |
| 長期債項 / 股東資金比率 (%) | 53.245% | 71.578% | 55.044% | 15.697% | 4.115% |
| 淨債項 / 股東資金比率 (%) | 40.608% | 107.695% | -17.191% | -62.732% | -66.088% |
| 淨現金 / (債項) ($) | (2.87億) | (5.70億) | 1.84億 | 10.43億 | 11.06億 |
| 每股淨現金 / (債項) ($) | (0.458) | (1.180) | 0.381 | 2.159 | -- |
| 總債項 / 資本運用比率 (%) | 52.181% | 80.767% | 37.358% | 14.270% | 4.310% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存貨周轉率日數 (日) | 12633.844日 | -- | -- | -- | -- |
| 應收貿易帳周轉率日數 (日) | 19.073日 | N/A | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | 1100.708日 | N/A | N/A | N/A | N/A |
| 備註： | 即時報價更新時間為27/03/2026 17:59 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) (千) | RMB -610,390 |
| 增長率 | 8.535% |
| 每股盈利/(虧損) | RMB -1.150 |
| 每股帳面資產淨值 (¥) | RMB 1.127 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
